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mount importance is the requirement to keep public health care at
the highest scientific level, based on evidence and medical
competence.
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Risk–benefit analysis should be the only basis for approval or reg-
istration of a new agent. However in addition to this, in Sweden,
for example, there is an obligation to promote cost-effective use
of drugs based on written information or workshops that include
subscribers. The National Institute of Clinical Excellence (NICE), a
special health authority of the British National Health Service,
deals with issues of cost and reimbursement. Regulators may
think of considering cost effectiveness when they request data
to substantiate efficacy of new anticancer agents as long as
patients are provided with best possible treatment. If, however,
society is not prepared to pay for new products, then they should
not be developed.
The goal of regulators is to limit unnecessary queries because
they needlessly increase the price of new drugs. A tradeoff exists
between quality of data and cost and data quality cannot be
lowered below some point. Industry dislikes segmented pricing,
but, particularly in the case of drug combinations, costs are pro-
hibitive for many countries. Differential pricing, based on the
region where a drug is being marketed, is one way to maximise
income. Regulatory authorities should take this factor into
account as they consider registering or licensing new anticancer
therapies.
Oncology involves a very special group of drugs. Is a new drug
development model for oncology drugs required to get them to
the market more quickly? Is conditional or accelerated approval
the best means to do so? In theory, conditional approval should
work although it is a relatively new process. Linking conditional
approval to conditional reimbursement, however, needs to be
very carefully evaluated as it should be possible to reassess the
cost–benefit of a conditionally approved therapy and take it off
the market if the cost–benefit analysis is not favourable (although
it would be a very difficult situation).
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This discussion on pharmacoeconomics involves not only indus-
try and academia, but also real people who have cancer. Some
people are treated and cured, but many have to live with the dis-
ease. Results of a keypad voting survey1 regarding the patient
access to anticancer therapy of 104 cancer advocates in May
2005 are shown in Table 1.
Interestingly, 100% of respondents from France indicated they
knewof no onewhohad been refused access to a cancer treatment
because of cost, whereas 100% of those from Poland responded
that they did. Clearly, cost is a factor, and the ability to access
new anticancer therapies varies greatly across Europe. Patients
do not think like consumers, though, because they do not care
about price; they just want the best treatment.
Therefore the question is that if a significant number of people
in Europe are not able to access technologies, what is the point of
developing or testing them? To ensure that real people can benefit
from new drugs means eliminating barriers to access, which
include the high price tag of the drugs and the time it takes for
registration or licensure. Clinical trials, regulatory agency review
and health technology assessments (HTAs) all take time, but
patients with life-threatening disease often do not have that
luxury.
The goals of new-drug development should be to provide
patients everywhere with timely access to safe and effective ther-
apies and to ensure that patients are not put at undue risk by tak-
ing innovative medicines. Thanks to the informed consent
process, patients understand risk and many are willing to accept
it by participating in clinical trials, even if they might not benefit
directly. Nevertheless, placebo-controlled trials present chal-
lenges because patients generally desire the opportunity to take
a potentially effective drug. Patients are likely to benefit from
the regular monitoring provided during clinical trials, but their
Table 1 – Results of a keypad voting survey of cancer
advocates, 2005
Survey item Response (%)
Are you aware of any cancer drugs that are
not available in your country but are available in others?
Yes 54
No 46
If yes, why is the drug not available?
The drug(s) are not licensed in my country 39
The public health authority will
not reimburse the drug(s)
56
Physicians will not prescribe the drug 0
Do not know 5
Do you know of anyone who has been refused
access to a cancer treatment, because it was
considered too expensive?
Yes 51
No 49
E J C S U P P L E M E N T S 5 ( 2 0 0 7 ) 2 –9 5
ability to access these trials usually depends on their clinician’s
involvement. Obtaining information about trials is often very
challenging for patients. The main issue is time, which cancer
patients lack.
HTAs sometimes present barriers to patient access. Different
countries take different approaches to HTAs and sometimes
arrive at different conclusions about a given treatment. The pro-
cess delays patient access. If a product is approved, is its use guar-
anteed or merely a recommendation? If it is not approved, the
regulatory agency needs to be transparent about the reason. Ben-
efits include more than just survival endpoints; quality of life and
symptom control are also very important. Extending life, if only
by a few months, can be critical to some patients. Having a life-
threatening disease also affects the degree to which patients
are willing to take risks. Therefore, measuring cost effectiveness
is complex, and priorities might be very different near the end
of a patient’s life.
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In principle, reimbursement for oncology therapeutics is extre-
mely good, especially in the United States. Medicare is required
to pay for indicated and compendia-listed off-label uses regard-
less of price. There is currently no system in place to measure
cost–benefit and impact of a new therapy. The trend in pricing
of new therapies has been steadily upward with cost in the range
of US $55,000 to $100,000 currently being obtained. Oncology drug
pricing has recently come under scrutiny, and if prices go too
high, the legislature would probably consider instituting some
limits. Co-payments are becoming a concern, however; Medicare
patients have to pay 20% out of their own pockets – a significant
sum considering the annual cost of some treatments. Neverthe-
less, secondary coverage is available, and many drug companies
have programs to help patients.
In the United States, payers and oncologists consider cost to
be of lower priority than clinical measures (Fig. 1). Sixteen payer
plans do not consider the cost of cancer treatment in their cover-
age decisions at all, largely because they follow Medicare cover-
age which is required to pay for approved oncology
therapeutics. However, oncologists’ treatment choices can be
affected by their perception of patients’ ability to pay.1
Favrille is the manufacturer of a personalised active immuno-
therapy product for B-cell non-Hodgkin’s lymphoma known as
mitumprotimut-T (FavId, Id-KLH, Idiotype vaccine) which is
given together with granulocyte-macrophage colony-stimulating
factor (Leukine, sargramostim, GM-CSF). It is custom-prepared
from individual patients’ tumour cells. Currently in phase III tri-
als, this immunotherapy appears to meet the criteria of what
the Centres for Medicare and Medicaid Services (CMS) would con-
sider an oncology therapeutic.
There are four main issues of concern for the reimbursement
of active immunotherapies in the United States: (1) Coverage
under Medicare Part B (physician administered) for a non-intrave-
nously administered (i.e sub-cutaneous or intra-Muscular) prod-
uct will require justification for the treatment to not be
considered self-administered (2) Co-administration of GM-CSF
(Leukine, sargramostim) will require coverage for use with the
active immunotherapy (3) 3rd party payer misconceptions that
this treatment should be covered in the same manner as prophy-
lactic vaccines, which are generally sub-optimal in the US, and
needs to be pro-actively addressed. (4) Coverage of a processing
fee could be problematic as this is usually associated with diag-
nostic procedures not therapeutics.
In the European Union, drug costs continue to be an issue
despite strict protocols for the use of expensive oncology prod-
ucts. Centralised procedures exist for the assessment of new
products and their cost-effectiveness, the most well known being
NICE in the United Kingdom. Furthermore, the majority of cancer
care in Europe is delivered through specialised, tertiary care cen-
tres or hospitals. These centres for the most part have fixed
annual budgets and treatment decisions are guided by set proto-
cols. An expensive new oncology therapeutic, such as an active
immunotherapy, must have sufficient supportive clinical and
pharmacoeconomic evidence to change these protocols and com-
pete for the limited financial resources of the institution. Glee-
vec is an example of an expensive, novel, oncology therapeutic
that has achieved success in Europe despite these hurdles – sales
in Europe as a percentage of global sales exceed those of the US.
In summary, reimbursement is not a significant concern if the
following criteria are met:
• Significant improvements in meaningful clinical endpoints are
demonstrated (e.g. time to disease progression, overall sur-
vival in randomised studies).
• Payment and reimbursement should be on a final per-product-
vial basis; avoid processing charges, which can complicate the
reimbursement process.
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